Intra-Cellular Therapies (ITCI) Receives Analyst Rating

Intra-Cellular Therapies (ITCI) : 5 brokerage houses believe that Intra-Cellular Therapies (ITCI) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Intra-Cellular Therapies (ITCI) : The consensus price target for Intra-Cellular Therapies (ITCI) is $76.57 for the short term with a standard deviation of $15.04. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $95, however, the pessimist price target for the company is $57.


Also, Piper Jaffray initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI). The current rating of the shares is Overweight, according to the research report released by the firm. The brokerage firm announces the price target at $57 per share. The rating by the firm was issued on June 2, 2016.

Intra-Cellular Therapies (NASDAQ:ITCI): After opening at $43.65, the stock dipped to an intraday low of $43.54 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $45 and the buying power remained strong till the end. The stock closed at $44.3 for the day, a gain of 1.93% for the day session. The total traded volume was 521,468. The stocks close on the previous trading day was $43.46.

ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *